UniQure (QURE) shares continue rally, surging 109% in recent Tuesday trading after Wells Fargo upgraded the company's stock to overweight from equalweight, with a $35 price target.
The upgrade follows the company's announcement that it reached an agreement with the US Food and Drug Administration on elements of an Accelerated Approval pathway for its drug AMT-130, a potential treatment for Huntington's disease.
Trading volume stood at over 53.6 million shares against a daily average of about 780,000.
Price: 15.22, Change: +7.93, Percent Change: +108.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.